Description
Phonyx Peptides Selank + Semax 10 mg is a research peptide blend containing 5 mg of Selank and 5 mg of Semax, for a clearly stated total content of 10 mg per labeled vial. The product is presented in a professional Phonyx Peptides container with a clean silver, white and gold label design, lot identification and expiry information.
This combination product is designed for research environments that require clearly identified peptide materials in a convenient dual-compound format. By bringing Selank and Semax together in one vial, the product offers a straightforward option for laboratories and researchers studying peptide combinations, formulation characteristics and research-use protocols.
The label clearly identifies the two compounds and their individual amounts: Sk 5 mg + Sx 5 mg, representing Selank 5 mg plus Semax 5 mg. The total labeled quantity is displayed as 10 mg.
Selank + Semax Research Blend
Selank and Semax are two distinct research peptides that are often discussed separately in peptide research. This Phonyx Peptides presentation combines both compounds in a single labeled research product, making the identity and ratio easy to recognize during laboratory inventory, sample organization and research documentation.
The 1:1 composition provides an equal labeled amount of each peptide: 5 mg Selank and 5 mg Semax. This makes the product particularly easy to identify for researchers looking for a balanced Selank and Semax combination rather than a single-compound vial.
The product should be evaluated according to the information printed on the original label and any accompanying documentation supplied by the manufacturer or distributor. The label confirms the stated composition, but it does not by itself establish purity, sterility, biological activity or suitability for a particular experiment.
Clearly Labeled 10 mg Format
The vial is marked 10 MG, with the individual composition shown as Sk 5 mg + Sx 5 mg. This clear presentation helps distinguish the product from single-peptide Selank or Semax products and supports more accurate laboratory stock control.
The product label also includes a lot number and expiry date, allowing researchers to record the relevant identification details when receiving or cataloguing the vial. For quality-control purposes, the lot and expiry information should be recorded exactly as displayed on the physical container.
Do not rely solely on the product name or external photographs when documenting a research material. Confirm the physical label, packaging condition and any available certificate of analysis before adding the vial to a laboratory inventory.
Phonyx Peptides Packaging
Phonyx Peptides Selank + Semax is supplied in a dark glass research vial with a metallic cap and a professionally designed label. The packaging is intended to keep the product clearly identifiable while presenting the compound names, individual amounts, total amount, lot number and expiry information in one location.
The silver and gold label design provides strong visual distinction for product photography, online catalogues and laboratory storage. The product name is displayed prominently, while the composition is placed directly below it for quick identification.
Keep the vial in its original packaging. Retaining the original label preserves the product name, composition, lot information and expiry details required for responsible research documentation.
Key Product Features
Dual-peptide composition: The vial contains both Selank and Semax in one combined research formulation.
Balanced 1:1 ratio: The label states 5 mg Selank plus 5 mg Semax.
10 mg total labeled content: The total quantity is clearly displayed on the front label.
Professional research packaging: The product is supplied in a dark glass vial with a sealed metallic cap and branded Phonyx Peptides label.
Lot identification: A visible lot number supports product tracking and internal laboratory records.
Expiry information: The label includes an expiry date for stock-control and documentation purposes.
Product Specifications
Brand: Phonyx Peptides
Product: Selank + Semax
Composition: Selank 5 mg + Semax 5 mg
Total labeled content: 10 mg
Composition ratio: 1:1
Product form: Labeled research peptide vial
Packaging: Dark glass vial with metallic cap
Lot information: Printed on the product label
Expiry information: Printed on the product label
Label designation: Research Use Only
Suitable Research Applications
The Selank + Semax blend can be catalogued for laboratory research involving peptide identity, combined-compound formulation, storage characteristics and analytical evaluation. Researchers may also use clearly documented dual-peptide materials when comparing single-compound and combination formats within an appropriately controlled research setting.
Any experimental application should be determined by qualified researchers according to applicable institutional procedures, local regulations, laboratory controls and validated methods. The product description should not be interpreted as a clinical claim or as evidence of an established effect in humans or animals.
The stated 5 mg plus 5 mg composition is useful for product comparison and inventory organization. It does not replace a certificate of analysis or independent analytical confirmation of the material.
What Research Shows About Selank and Semax
Selank is a synthetic heptapeptide derived from tuftsin and has been investigated mainly in relation to anxiety-related behaviour, stress responses and neurochemical regulation. In a comparative clinical study indexed in PubMed, 62 patients with generalized anxiety disorder and neurasthenia were evaluated; the Selank group showed anxiolytic effects comparable to medazepam, while the authors also reported antiasthenic and psychostimulant effects. The study additionally examined changes in enkephalin-related biomarkers . These results are useful for describing the research direction, but they do not establish that every Selank product produces a guaranteed clinical effect.
Mechanistic research has examined whether Selank influences GABAergic signalling and changes the expression of selected genes associated with nervous-system function . This supports describing Selank as a peptide of interest in neurochemical and stress-response research, not as a proven replacement for an approved anxiolytic or as a guaranteed cognitive enhancer.
Semax is a synthetic peptide related to ACTH(4–7) and the Pro-Gly-Pro sequence. Human clinical research has investigated Semax as an adjunct in the acute period of hemispheric ischemic stroke. One PubMed-indexed study compared 30 Semax-treated patients with 80 control patients receiving conventional therapy and reported an influence on the rate of recovery of neurological functions . This was a specific clinical setting and must not be converted into a general promise of improved memory, focus, mood or athletic performance.
Additional experimental work in rats with focal cerebral ischemia found that Semax altered the expression of genes related to immune and vascular systems, suggesting possible neuroprotective mechanisms . Because this evidence is largely context-specific and includes animal research, it should be presented as experimental evidence rather than proof of a human therapeutic effect.
The present Phonyx Peptides vial combines Selank and Semax in a 1:1 labeled ratio, but the cited studies evaluated individual peptides or specific clinical formulations rather than this exact commercial blend. The product therefore belongs in research on peptide identity, formulation and biological pathways; it should not be marketed as a clinically validated Selank + Semax treatment.
Quality and Documentation
For responsible research purchasing, retain the original label, lot number, expiry date, order information and any manufacturer documentation supplied with the vial. These details help maintain a traceable record from delivery through storage and laboratory use.
Where a certificate of analysis is available, compare its product name, lot number, test method, reported purity and test date with the physical vial. Documentation should correspond to the exact lot being evaluated rather than to a different batch or similarly named product.
The appearance of a vial cannot confirm peptide identity or purity. Unusual particles, damaged packaging, an unreadable label, leakage or a mismatch between the documentation and the physical product should be documented and referred to the supplier before the material is used in research.
Storage and Handling
Store the vial according to the instructions supplied with the product and any applicable laboratory standard operating procedure. Protect it from unsuitable temperatures, direct light, moisture, contamination and unnecessary handling.
Do not remove or replace the original label. The lot and expiry details are important for traceability, particularly when several peptide products are stored in the same laboratory environment.
The product should be handled only by trained personnel using appropriate laboratory controls. Researchers should establish their own validated storage, preparation, handling and disposal procedures rather than relying on general online product descriptions.
Why Choose Phonyx Peptides Selank + Semax?
This product offers a clear and convenient way to source Selank and Semax together in a single 10 mg research peptide vial. The labeled 5 mg plus 5 mg composition, balanced ratio, professional Phonyx Peptides packaging, lot identification and expiry information make the product straightforward to catalogue and distinguish from single-peptide alternatives.
For online product presentation, the strongest commercial advantages are the clearly visible composition, recognizable brand design and practical dual-peptide format. Accurate labeling and transparent product information help researchers compare materials and maintain better inventory records.
Research Use Only. Not intended for human use, veterinary use, diagnosis, treatment or consumption.
Reference
[1] Phonyx Peptides official website
[2] Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia
[3] Selank administration affects the expression of some genes
[4] Effectiveness of Semax in acute hemispheric ischemic stroke
[5] Semax gene expression study in rat focal ischemia